PMEF
INZY

Point72 Middle East FZE’s Inozyme Pharma INZY Stock Holding History

Point72 Middle East FZE’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,897
Closed -$10.9K – 1800
2023
Q1 		$10.9K Buy
+1,897
New +$5.01K ﹤0.01% 1479

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Point72 Middle East FZE's INZY Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Inozyme Pharma (INZY) in Q2 2023, closing a stake of 1,897 shares — an estimated $10.9K sold.

Point72 Middle East FZE first reported a position in INZY in Q1 2023 and held it in 1 quarter. The position peaked at $10.9K in Q1 2023. 74 funds tracked by Wall St. Rank hold INZY as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Inozyme Pharma position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,897 Inozyme Pharma shares in Q2 2023, an estimated $10.9K.
  • Point72 Middle East FZE first reported a position in Inozyme Pharma in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Inozyme Pharma position peaked at $10.9K in Q1 2023.
  • 74 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.